NCT06619990View on ClinicalTrials.gov

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Ulcerative Colitis (UC)
Interventions
BIOLOGICAL

XmAb942

Antibody

DRUG

Placebo

Placebo

Trial Locations (2)

6009

RECRUITING

Linear Clinical Research, Nedlands

6027

RECRUITING

Linear Clinical Research, Joondalup

Sponsors
All Listed Sponsors
collaborator

Xencor, Inc.

INDUSTRY

lead

GALE Therapeutics Inc.

INDUSTRY